NUCLEAI
Nucleai is a spatial biology company that has developed an AI-powered platform to enhance drug development and improve patient outcomes. Nucleai’s platform leverages unique tissue datasets to produce insights into cancer biology, increasing clinical trial efficacy and improving patient care. Nucleai works with leading pharmaceutical companies, licensing its research platform for internal use, and collaborating in biomarkers discovery projects.
NUCLEAI
Industry:
Artificial Intelligence Health Care Machine Learning
Founded:
2017-01-01
Address:
Tel Aviv, Tel Aviv, Israel
Country:
Israel
Website Url:
http://www.nucleaimd.com
Total Employee:
11+
Status:
Active
Email Addresses:
pharma@nucleaimd.comjohn_smith@nucleaimd.com
johnsmith@nucleai.ai
john_smith@nucleai.ai
Total Funding:
46.5 M USD
Technology used in webpage:
SPF SSL By Default Google Analytics Google Tag Manager Google Universal Analytics Global Site Tag Amazon IPv6 Google Apps For Business Cloudflare Hosting
Similar Organizations
mfine
Mfine is a health-tech startup developing an AI-powered telemedicine mobile app.
Navina
Navina develops an AI-driven platform that restructures patient data into intuitive patient portraits for better diagnoses and care.
Neteera
Neteera developed an AI-powered sensing platform to reduce treatment failures & improve outcomes in health screening, diagnosis & treatment.
TuSimple
TuSimple is a self-driving truck company developing technology that allows them to drive from depot-to-depot without human intervention.
Visit
AI driven chatbot to provide health advice within minutes.
Current Advisors List
Board_member
Board_member
2020-07-07
Board_member
Board_member
2022-01-01
Board_member
2018-02-01
Board_member
Current Employees Featured
Avi Veidman CEO @ Nucleai
CEO
2017-01-01
Eliron Amir COO @ Nucleai
COO
2017-01-01
Ori Zelichov VP Clinical Development @ Nucleai
VP Clinical Development
2019-10-01
Lotan Chorev VP R&D @ Nucleai
VP R&D
2017-01-01
Albert Achtenberg CTO @ Nucleai
CTO
2019-09-01
Founder
Investors List
Fosun RZ Capital
Fosun RZ Capital investment in Series B - Nucleai
Debiopharm Innovation Fund
Debiopharm Innovation Fund investment in Series B - Nucleai
Grove Ventures
Grove Ventures investment in Series B - Nucleai
Vertex Ventures Israel
Vertex Ventures Israel investment in Series B - Nucleai
Section 32
Section 32 investment in Series B - Nucleai
Sanofi Ventures
Sanofi Ventures investment in Series B - Nucleai
Vertex Ventures Israel
Vertex Ventures Israel investment in Series A - Nucleai
Grove Ventures
Grove Ventures investment in Series A - Nucleai
Debiopharm Innovation Fund
Debiopharm Innovation Fund investment in Series A - Nucleai
Grove Ventures
Grove Ventures investment in Seed Round - Nucleai
Official Site Inspections
http://www.nucleaimd.com
- Host name: cloudproxy10179.sucuri.net
- IP address: 192.124.249.179
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Nucleai"
Nucleai - Crunchbase Company Profile & Funding
Contact Email pharma@nucleaimd.com Nucleai is a spatial biology company that has developed an AI-powered platform to enhance drug development and improve patient outcomes. …See details»
AI-Driven Spatial Biomarkers
Our platform pioneers AI-driven spatial biomarker analysis, offering a first-of-its-kind multimodal solution. It ingests images from various modalities (H&E, IHC, multiplex immunofluorescence, …See details»
Nucleai (Israel) Funding: $60.5M - Medical Startups
Nucleai aims to Improve cancer diagnostics making it accurate, effective, accessible and efficient in order to treat patients better by using Machine Learning, Deep Learning, and Machine Vision...See details»
Nucleai Company Profile | Management and Employees List
John_Smith@nucleaimd.com: 5: first + last: JohnSmith@nucleai.ai: 6: first_last: John_Smith@nucleai.ai: Your Questions, Our Answers Get Free Access to Nucleai Contacts …See details»
Leadership - Nucleai
Leadership Transforming Precision Medicine with AI-powered Pathology Our team’s work is a unique collaboration of experienced AI technologists, physicians and exceptional healthcare …See details»
Nucleai in The News
400 N Aberdeen St, Ste 951, Chicago, IL 60642 4 Ein Zeitim St, Tel Aviv, IsraelSee details»
Nucleai - LinkedIn
Nucleai | 17,488 עוקבים על לינקדאין. The leading Spatial Biology Software Platform for Precision Medicine. | Nucleai Brings AI-powered spatial biology technology to the forefront of precision medicine to improve drug development, clinical treatment decisions, and patient outcomes. Nucleai works with leading pharmaceutical companies, licensing its research platform for …See details»
Nucleai Secured $6.5m Series-A Initial Closing Led by
Jul 7, 2020 Tel Aviv, Israel, Lausanne, Switzerland–July 7th 2020 – Nucleai (www.Nucleaimd.com), an Israeli start-up providing an artificial intelligence-powered precision …See details»
Working at nucleaimd | Mission, Leadership, and Benefits - Blind
Read about nucleaimd mission, management, benefits and perks, including insurance benefits, retirement benefits, and vacation policy.See details»
Nucleai and Merck KGaA - Business Wire
Jun 24, 2021 CHICAGO--(BUSINESS WIRE)--Nucleai (www.nucleaimd.com), a precision medicine company using AI-powered image analysis technology to support novel pathology …See details»
Nucleai MD - Overview, News & Similar companies | ZoomInfo.com
Www.nucleaimd.com. Revenue <$5 Million. Industry Hospitals & Clinics Healthcare . Recent News & Media. No recent news or media. Overview ; Org Chart ; Who is Nucleai MD. Nucleai MD is a company that operates in the Hospital & Health Care industry. It employs 11-20 people and has $1M-$5M of revenue.See details»
Nucleai Company Overview, Contact Details & Competitors | LeadIQ
Strategic Partnerships Nucleai Inc. has been actively forming strategic partnerships with companies like Proscia Inc., Bgparkdistrict, and GoPath Global, Inc. These collaborations …See details»
Nucleai and Debiopharm Launch Research Collaboration
Jan 14, 2021 Tel Aviv, Israel, Lausanne, Switzerland –Thursday, January 14th 2021 – Nucleai (www.Nucleaimd.com), a global provider in pathology-based biomarker discovery, and …See details»
Nucleai Secured $6.5m Series-a Initial Closing Led by Debiopharm …
Nucleai– (www.Nucleaimd.com), an Israeli start -up providing an artificial intel ligence-powered precision oncology platform for research and treatment decisions and Debiopharm …See details»
AI Transforms Drug Discovery And Precision Medicine - Forbes
1 day ago AI helps make medicine more personal at creation, reshaping drug development and design and improving the efficacy of clinical trials.See details»
Nucleai (Israel) Funding: $60.5M - AI startups
Oct 16, 2024 Nucleai aims to Improve cancer diagnostics making it accurate, effective, accessible and efficient in order to treat patients better by using Machine Learning, Deep …See details»
Nucleai and Debiopharm Launch Research ... - NS Medical Devices
Jan 15, 2021 Nucleai (www.Nucleaimd.com), a global provider in pathology-based biomarker discovery, and Debiopharm (www.debiopharm.com), a Swiss-based biopharmaceutical …See details»
Nucleai Secured $6.5M Series-A Initial Closing Led by Debiopharm …
Jul 7, 2020 TEL AVIV and LAUSANNE, Switzerland, July 7, 2020 /PRNewswire/ -- Nucleai (www.Nucleaimd.com), an Israeli start-up providing an artificial intelligence-powered precision …See details»
Nucleai and Merck KGaA Darmstadt, Germany Launch ... - BioSpace
Jun 24, 2021 Nucleai (www.nucleaimd.com), and Merck KGaA, Darmstadt, Germany, announced that they have entered into a long-term collaboration to leverage Nucleai's image analysis and biomarker discovery platform for several Merck KGaA, Darmstadt, Germany clinical stage oncology assets.See details»
Nucleai Secured $6.5M Series-A Initial Closing Led by ... - BioSpace
Jul 7, 2020 Nucleai (www.Nucleaimd.com), an Israeli start-up providing an artificial intelligence-powered precision oncology platform for research and treatment decisions and Debiopharm …See details»